Cargando…

Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes

Hereditary pancreatic cancer, which includes patients with familial pancreatic cancer (FPC) and hereditary pancreatic cancer syndromes, accounts for about 10% of all pancreatic cancer diagnoses. The early detection of pre-cancerous pancreatic cysts has increasingly become a focus of interest in rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Ardeshna, Devarshi R., Rangwani, Shiva, Cao, Troy, Pawlik, Timothy M., Stanich, Peter P., Krishna, Somashekar G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313108/
https://www.ncbi.nlm.nih.gov/pubmed/35884779
http://dx.doi.org/10.3390/biomedicines10071475
_version_ 1784753998243299328
author Ardeshna, Devarshi R.
Rangwani, Shiva
Cao, Troy
Pawlik, Timothy M.
Stanich, Peter P.
Krishna, Somashekar G.
author_facet Ardeshna, Devarshi R.
Rangwani, Shiva
Cao, Troy
Pawlik, Timothy M.
Stanich, Peter P.
Krishna, Somashekar G.
author_sort Ardeshna, Devarshi R.
collection PubMed
description Hereditary pancreatic cancer, which includes patients with familial pancreatic cancer (FPC) and hereditary pancreatic cancer syndromes, accounts for about 10% of all pancreatic cancer diagnoses. The early detection of pre-cancerous pancreatic cysts has increasingly become a focus of interest in recent years as a potential avenue to lower pancreatic cancer incidence and mortality. Intraductal papillary mucinous cystic neoplasms (IPMNs) are recognized precursor lesions of pancreatic cancer. IPMNs have high prevalence in patients with hereditary pancreatic cancer and their relatives. While various somatic mutations have been identified in IPMNs, certain germline mutations associated with hereditary cancer syndromes have also been identified in IPMNs, suggesting a role in their formation. While the significance for the higher prevalence of IPMNs or similar germline mutations in these high-risk patients remain unclear, IPMNs do represent pre-malignant lesions that need close surveillance. This review summarizes the available literature on the incidence and prevalence of IPMNs in inherited genetic predisposition syndromes and FPC and speculates if IPMN and pancreatic cancer surveillance in these high-risk individuals needs to change.
format Online
Article
Text
id pubmed-9313108
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93131082022-07-26 Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes Ardeshna, Devarshi R. Rangwani, Shiva Cao, Troy Pawlik, Timothy M. Stanich, Peter P. Krishna, Somashekar G. Biomedicines Review Hereditary pancreatic cancer, which includes patients with familial pancreatic cancer (FPC) and hereditary pancreatic cancer syndromes, accounts for about 10% of all pancreatic cancer diagnoses. The early detection of pre-cancerous pancreatic cysts has increasingly become a focus of interest in recent years as a potential avenue to lower pancreatic cancer incidence and mortality. Intraductal papillary mucinous cystic neoplasms (IPMNs) are recognized precursor lesions of pancreatic cancer. IPMNs have high prevalence in patients with hereditary pancreatic cancer and their relatives. While various somatic mutations have been identified in IPMNs, certain germline mutations associated with hereditary cancer syndromes have also been identified in IPMNs, suggesting a role in their formation. While the significance for the higher prevalence of IPMNs or similar germline mutations in these high-risk patients remain unclear, IPMNs do represent pre-malignant lesions that need close surveillance. This review summarizes the available literature on the incidence and prevalence of IPMNs in inherited genetic predisposition syndromes and FPC and speculates if IPMN and pancreatic cancer surveillance in these high-risk individuals needs to change. MDPI 2022-06-22 /pmc/articles/PMC9313108/ /pubmed/35884779 http://dx.doi.org/10.3390/biomedicines10071475 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ardeshna, Devarshi R.
Rangwani, Shiva
Cao, Troy
Pawlik, Timothy M.
Stanich, Peter P.
Krishna, Somashekar G.
Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes
title Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes
title_full Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes
title_fullStr Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes
title_full_unstemmed Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes
title_short Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes
title_sort intraductal papillary mucinous neoplasms in hereditary cancer syndromes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313108/
https://www.ncbi.nlm.nih.gov/pubmed/35884779
http://dx.doi.org/10.3390/biomedicines10071475
work_keys_str_mv AT ardeshnadevarshir intraductalpapillarymucinousneoplasmsinhereditarycancersyndromes
AT rangwanishiva intraductalpapillarymucinousneoplasmsinhereditarycancersyndromes
AT caotroy intraductalpapillarymucinousneoplasmsinhereditarycancersyndromes
AT pawliktimothym intraductalpapillarymucinousneoplasmsinhereditarycancersyndromes
AT stanichpeterp intraductalpapillarymucinousneoplasmsinhereditarycancersyndromes
AT krishnasomashekarg intraductalpapillarymucinousneoplasmsinhereditarycancersyndromes